COM-902

N/A

Report date: 2025/05/15 11:44:54

Base Information

Drug NameCOM-902
Drug Alias NameCOM-902CGEN-15137
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsColonic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCompugen Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcCompugen Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsOvarian NeoplasmsColonic Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A